CLC bio part of $7.8M EU STATegra grant to develop integral analysis platform for epigenetics

Aarhus, Denmark -- December 12, 2012 -- Today CLC bio announced the participation in the European FP7 project, STATegra, and receives 1.3 million US Dollars out of the total $7.8M project budget.

STATegra aims to develop a user-friendly integral analysis platform for different omics data that is capable of providing a more efficient use of genomics technologies. As a first, this project will generate and integrate data obtained in proteomic, metabolomic and epigenomic experiments.

"One of the big challenges today is going past the raw sequence data and getting to grips with the complexity of epigenetic processes - how, when, and why are certain genes switched off or expressed?"

Dr. Michael Lappe continues, "By working together with leading experimental researchers and using our in-house competences in world-class software-engineering, we aim to leverage a framework which makes this extremely complex network biology understandable. Ultimately our tools will facilitate the translation of massive amounts of data into useful insights that can be applied in clinical settings."
Senior Bioinformatics Scientist at CLC bio, Dr. Michael Lappe

About STATegra

The STATegra project aims to provide novel methods and solid statistical foundations to the analysis of a number of different cutting-edge experimental datasets. CLC bio will make these new methods available in the context of their user-friendly software packages and enhance them with suitable visualisation tools. The combination of statistical and visual analysis is key in order to provide a supportive discovery environment for biomedical researchers. Within the overall project, also methods for the validation and design of follow-up studies are implemented. Utilizing and validating existing datasets, STATegra is also going to feed its experimental results back into the public domain.

STATegra project partners

The project partners in STATegra are CLC bio (Denmark), Biomax Informatics AG (Germany), Karolinska Institutet (Sweden), Imperial College of Science, Technology and Medicine (UK), Foundation for Research and Technology - Hellas (Greece), Institut d’Investigació Biomèdica de Bellvitge (Spain), University of Amsterdam (Holland), University of Leiden (Holland), the Ludwig-Maximilians University of Munich (Germany), University of California (USA). The project is coordinated by Dr. Ana Conesa from the Computational Medicine Institute of the Prince Felipe Research Centre (Spain).

About CLC bio

http://www.clcbio.com/about

Contact CLC bio

Lasse Görlitz, VP of Communications
Tel: +1 (617) 765 0687
E-mail: lgoerlitz@clcbio.com